Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Hormone Receptor-Positive Metastatic Breast Cancer: a Pooled Analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) Trials
Despite advances in phenotypic and mechanistic characterization of three distinct permeability pathways, development of experimental agents that specifically target these pathways, and remarkable efficacy in preclinical models, pathway-targeted therapies have not been tested in human subjects
We also thank all lab members for helpful discussions
Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment
10.1016/j.jep.2019.112229 158 WangY.OcampoM
He X, Han Z, Ruan Y, Wang Z, Liao B, Li X, et al